Bio Pharma Dive
APRIL 19, 2022
Regeneron has agreed to purchase Checkmate Pharmaceuticals for $250 million, the first acquisition of a publicly traded company in the biotech's nearly 35-year history.
World of DTC Marketing
APRIL 21, 2022
TV creates awareness quickly when you have a big audience, but TV is a waste of money when your audience is small. I can get better results using digital laser targeting and targeted print ads, but DTC marketers are like TV because it makes them feel important within their company. Tepezza has been running many ads on TV, but it’s a waste of money. The money could have been better spent to learn all they can about their audience and take the message to where they are, either in print or online.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
APRIL 21, 2022
A study has found that there is still a very high level of inappropriate antibiotic prescribing to patients in the US, particularly to older and Black patients. Sifting through data from around seven billion outpatient visits to doctor’s offices, hospital clinics and emergency departments over a seven-year period, the researchers found that almost three-quarters (74%) of antibiotics prescribed to patients aged 65 years or older, and two thirds (64%) to Black patients, were unnecessary.
Pharma Times
APRIL 22, 2022
Researchers were able to detect specific combinations of genetic alterations which may hold key to the growth of cancers
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Bio Pharma Dive
APRIL 18, 2022
The planned job cuts were announced days after Imara — one of three spinouts from the drug accelerator Cydan Development, stopped development of its top medicine.
World of DTC Marketing
APRIL 20, 2022
We just finished talking to over 200 hundred HCPs about pharma marketing and salespeople to measure any differences since before the pandemic. Attitudes are indeed changing, but one need remains clear: access to data obtained during clinical and ongoing trials. We’ve all heard that digital is the way to reach HCPs, and we found out that’s still mostly true, but not all digital tactics are created equal.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Times
APRIL 22, 2022
Infertility is estimated to affect one in seven couples across the UK and can have a profound effect on mental health
Bio Pharma Dive
APRIL 19, 2022
Unlike treatments from Akebia and FibroGen, GSK's drug hasn't been tied to a higher risk of heart problems, potentially easing the agency's concerns.
World of DTC Marketing
APRIL 19, 2022
Before most drugs are launched, much time and effort are spent developing marketing plans and getting approval. However, given the rapid changes in the market and the realization that too many tactics are more hype than reality, fixed marketing plans are a waste of time. There are three essential elements of any good marketing plan: brand objective, Strategy, and tactics.
pharmaphorum
APRIL 22, 2022
Ampio Pharma’s candidate therapy for knee osteoarthritis has been knocked back by the FDA, which will likely now require a new clinical trial of the drug before it will consider a review. Shares in the US biotech have fallen sharply after it revealed that the regulator did not accept changes to a phase 3 trial of the drug – called Ampion – that the company put forward in order to make it serve as a confirmatory pivotal study.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
XTalks
APRIL 18, 2022
Newark, New Jersey-based RoboBurger claims to have created America’s first burger vending machine and is now looking to expand. The startup aims to bring its burger vending machines to the Philadelphia area within the year after launching its first outpost at the Newport Centre Mall in North Jersey last month. So, how does the unusual vending machine work?
Bio Pharma Dive
APRIL 18, 2022
The companies have halted testing in kidney and bladder cancer, one month after ending a skin cancer study. Nektar executives are now preparing plans to conserve cash.
BioPharma Reporter
APRIL 19, 2022
Modernaâs bivalent COVID-19 booster vaccine candidate, mRNA-1273.211, demonstrated superior neutralizing titers compared to the original mRNA-1273 booster dose against all variants of concern, including Omicron, according to data released by the company this week.
pharmaphorum
APRIL 19, 2022
Ehab Youssef, area head of Europe North at Roche Pharmaceuticals, tells us why European countries need interoperability to ensure a more effective overall European healthcare system. COVID spotlighted the vulnerability of the healthcare system and the need for structural and technological change to help manage such as crisis. Though some regions have started to make the necessary changes, Youssef says Europe is lagging. “In general, there is a good progression in almost every country.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
XTalks
APRIL 18, 2022
Top COVID-19 mRNA vaccine maker BioNTech is setting out to explore new and improved delivery technologies for mRNA vaccines, recently announcing a collaboration with New Jersey-based lipid nanocrystal developer Matinas BioPharma. The $2.75 million deal will allow BioNTech to tap into Matinas’ Lipid Nanocrystal (LNC) Delivery Platform Technology to develop novel vaccine formulations, including a potential oral solution.
Bio Pharma Dive
APRIL 18, 2022
Early analysis of a key clinical trial showed a potentially increased risk of death in cancer patients who received a combination treatment that included TG Therapeutics' approved medicine, Ukoniq.
Outsourcing Pharma
APRIL 20, 2022
The two-day Oracle Health Sciences Connect will gather an array of research experts to discuss how to make the most of emerging technologies and practices.
pharmaphorum
APRIL 22, 2022
Astellas has said it will book a $170 million impairment charge in its fourth quarter results as a result of a decision to halt the development of three gene therapy candidates for Duchenne muscular dystrophy in preclinical development. The write-down comes in the wake of problems affecting the Japanese drugmaker’s AT132 gene therapy candidate for rare disease X-linked myotubular myopathy (XLMTM), which was placed on clinical hold by the FDA last year after four patient deaths liked to pos
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Times
APRIL 20, 2022
‘The Eyes Have It’ partnership will highlight the importance of eye health
Bio Pharma Dive
APRIL 19, 2022
The new site in Frederick, Maryland will be used to produce Yescarta, which this month won an expanded approval that substantially widens its market.
XTalks
APRIL 19, 2022
From vintage Coca-Cola coolers to non-edible Pringles, consumers are developing an appetite for non-fungible tokens (NFTs). The burgeoning technology allows people to secure unique ownership of artwork, videos, photos and other digital content on the blockchain. Now, food NFT adoption is picking up steam across the food and beverage industry, with many fast-food chains displaying interest in them.
pharmaphorum
APRIL 19, 2022
AstraZeneca and Daiichi Sankyo should only have to wait for six months to hear from the FDA if it will approve their HER2 drug Enhertu for non-small cell lung cancer (NSCLC) and add to its current uses in breast and gastric cancer. The US regulator has kicked off a priority review of Enhertu (trastuzumab deruxtecan) as a treatment for NSCLC with HER2 mutations after prior systemic therapy, setting up a decision in the third quarter of this year.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharma Times
APRIL 21, 2022
The new guidelines focus on key areas of prescription, management of withdrawal and severity of withdrawal symptoms
Bio Pharma Dive
APRIL 20, 2022
Backed by $110 million in venture funding, Satellite is led by Dave Lennon, formerly head of Novartis Gene Therapies.
JAMA Internal Medicine
APRIL 17, 2022
This nonrandomized controlled trial uses a modified World Health Organization ordinal scale to assess whether awake prone positioning was associated with improved clinical outcomes among patients with COVID-19–related hypoxemia who require supplemental oxygen but have not received invasive mechanical ventilation.
pharmaphorum
APRIL 20, 2022
A meta-analysis of published studies looking at web- app- or telehealth-based therapy for osteoarthritis has concluded that they outperform standard approaches to care. The study – published in the journal Osteoarthritis and Cartilage – focused on patients with osteoarthritis of the hip or knee, and compared the digitally-delivered exercises to standard approaches such as in-person physiotherapy, other forms of care, waitlisting and patient education.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharma Times
APRIL 20, 2022
Company at the forefront of developing personalised treatments against invasive cancer has raised 15m euros to conduct clinical trials
Bio Pharma Dive
APRIL 21, 2022
List prices for branded medicines rose by nearly 5% last year, according to IQVIA, a figure that fell to 1% after accounting for rebates and discounts.
XTalks
APRIL 21, 2022
New York-based startup BUBLUV, Inc. recently launched its first product: a better-for-you, ready-to-drink bottled bubble tea. BUBLUV claims to be the first of its kind on the market and is available exclusively on the company’s direct-to-consumer (DTC) website. So, how does the brand differ from other bubble teas? While many bubble teas often lack nutritional value, BUBLUV boasts no added sugar, no artificial ingredients and contains less than 50 calories per bottle.
pharmaphorum
APRIL 19, 2022
Just days after dosing its first patient in a Duchenne muscular dystrophy trial, US biotech PepGen has pushed the button on an initial public offering (IPO). The Boston-based company has filed with the US Securities and Exchange Commission to raise up to $115 million from the IPO, according to a Renaissance Capital report. The funding will be used to continue the clinical development of lead oligonucleotide PGN-EDO51 for DMD, as well as two other oligo drugs PGN-EDODM1 for myotonic dystrophy ty
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
333 
Let's personalize your content